CSIMarket Company Name, Ticker, Customers, else..
 
Firefly Neuroscience Inc   (NASDAQ: AIFF)
    Sector • Technology    Industry • Software & Programming
   Industry • Software & Programming
   Sector • Technology
 
Price: $1.1300 $0.03 2.727%
Day's High: $1.1299999952316284 Week Perf: 0.89 %
Day's Low: $ 1.08 30 Day Perf: 0.89 %
Volume (M): 48,180 52 Wk High: $ 3.15
Volume (M$): $ 0 52 Wk Avg: $1.61
Open: $1.09 52 Wk Low: $0.62



 Market Capitalization (Millions $) 23
 Shares Outstanding (Millions) 21
 Employees 17
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Business Description


Firefly Neuroscience, Inc. is an artificial intelligence company that develops the Firefly Platform, which integrates hardware, software, and data infrastructure to capture and analyze standardized EEG and ERP brain activity assessments at the point of care. Their FDA-cleared Evoke System is used in clinical settings to provide clinicians with electrophysiological data that complements traditional cognitive and behavioral assessments, supporting diagnosis and treatment planning for neurological and psychiatric conditions.


   Company Address: 1100 Military Road Kenmore 14217 NY
   Company Phone Number: 237-6412   Stock Exchange / Ticker: NASDAQ AIFF


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADBE   -8.58%    
IT   -6.03%    
• View Complete Report
   



Clinical Study

Augmenting Brain Health Firefly Neuroscience Unveils Promising EEG Analytics in Drug Development and Neuropsyc...

Published Sat, Jan 25 2025 5:55 PM UTC

In a groundbreaking development poised to transform the landscape of drug development and neuropsychiatric care, Firefly Neuroscience has announced a series of publications demonstrating the efficacy of its advanced EEG analytics platform. Highlighting a growing body of clinical evidence, these publications emphasize the potential of Firefly s FDA-cleared Brain Network Analy...
Partnership

Firefly Neuroscience and Bright Minds Biosciences Collaborate to Harness AI for Promising Neurotechnology Advancements

Published Wed, Oct 16 2024 1:21 PM UTC

In a significant development within the biotechnology sector, Firefly Neuroscience has announced a collaboration with Bright Minds Biosciences to analyze data derived from a successful Phase 1 clinical study. This partnership aims to utilize Firefly’s innovative artificial intelligence (AI) technology, specifically its FDA-cleared Brain Network Assessment (BNA) platform, t...
Clinical Study

Firefly Neuroscience Embarks on Groundbreaking Phase 1 Study for SP-624 Pioneering Biomarker Identification in Fema...

Published Tue, Oct 15 2024 1:01 PM UTC

In a significant advancement in the field of neurology, Firefly Neuroscience has announced the launch of a Phase 1 clinical study utilizing its cutting-edge Brain Network Analytics (BNA) platform in the evaluation of SP-624. This represents not only a pivotal moment for the company s research but also a potential milestone in the treatment of Major Depressive Disorder (MDD) ...
Clinical Study

Illuminating the Future of Neuroscience Drug Development Firefly Neuroscience’s Revolutionary BNA Technology

Published Fri, Sep 20 2024 1:00 PM UTC

: Firefly Neuroscience, a pioneering company in the field of artificial intelligence, is making significant strides in the realm of neuroscience drug development through the advancement of its Brain Network Analytics (BNA) technology. Following successful collaborations with major pharmaceutical institutions, Takeda and Novartis, Firefly s innovations promise to reshape ho...
Partnership

Firefly Neuroscience and Zeto Collaborate to Expand BNA Technology Access in Healthcare,

Published Tue, Sep 10 2024 1:00 PM UTC

Firefly Neuroscience Partners with Zeto to Enhance Distribution of BNA Technology Firefly Neuroscience Inc. a company focused on innovative brain health solutions, recently announced a significant partnership with Zeto, a developer of advanced medical technology. This collaboration aims to integrate and distribute Firefly’s proprietary Brain Network Activation (BNA) techno...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 12.93
Price to Sales (Expected) -
Price to Book 1.59
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.4
Working Capital Ratio 4.9
Leverage Ratio (MRQ) 0.14
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.46 $
Revenues (TTM) 0.09 $
Cash Flow (TTM) -
Cash 0.45 $
Book Value 0.71 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 105,824
Net Income per Employee (TTM) -555,059
Receivable Turnover Ratio (TTM) 9.48
Inventory Turnover Ratio (TTM) 11.9
Asset Turnover Ratio (TTM) 0.14

Profitability Ratios Current
Gross Margin (MRQ) 49.22 %
Operating Margin (MRQ) -384.05 %
Net Margin (MRQ) -385.99 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Firefly Neuroscience Inc's Segments
Product and Service Other    3.11 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.